Association between polymorphism of tumor necrosis factor-α promoter and response to lamivudine treatment in patients with chronic hepatitis B

Yong Kwang Park; Jung Min Lee; Do Young Kim; Hye Young Chang; Ja Kyung Kim; Chun Kyon Lee; Jun Yong Park; Sang Hoon Ahn; Kwan Sik Lee; Kwang Hyub Han

doi:10.1007/s10620-009-0983-1

Association between polymorphism of tumor necrosis factor-α promoter and response to lamivudine treatment in patients with chronic hepatitis B

Yong Kwang Park, Jung Min Lee, Do Young Kim, Hye Young Chang, Ja Kyung Kim, Chun Kyon Lee, Jun Yong Park, Sang Hoon Ahn, Kwan Sik Lee, Kwang Hyub Han

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Abstract

Background: TNF-α promoter polymorphism is known to play an important role in the immunopathogenesis of infection of hepatitis B virus. Aims: We investigated whether polymorphisms of TNF-α promoter at position -308 or -238 had associations with the response to lamivudine treatment. Methods: A total of 89 healthy subjects (control group) and 225 patients with chronic hepatitis B treated with lamivudine were included in this study. Polymorphisms of TNF-α promoter at position -308 and -238 were analyzed by polymerase chain reaction. Recruited patients were classified according to the outcome of lamivudine treatment into the responder (103 patients) or non-responder (122 patients) group. Results: The numbers of A allelic polymorphism of TNF-α promoter at position -238 were four (2.2%) in the control, five (2.4%) in the responder and 19 (7.8%) in the non-responder group. The A allele was noted significantly more frequently in the responder than non-responder group (P = 0.012). At position -308, a significant difference was observed between the control group (14; 7.9%) and total chronic hepatitis B patients (15; 3.3%) (P = 0.015). Conclusions: Our study demonstrated that the non-response to lamivudine treatment in patients with chronic hepatitis B might be related to the A allelic polymorphism of TNF-α promoter at position -238.

Original language	English
Pages (from-to)	2043-2048
Number of pages	6
Journal	Digestive diseases and sciences
Volume	55
Issue number	7
DOIs	https://doi.org/10.1007/s10620-009-0983-1
Publication status	Published - 2010 Jul

Bibliographical note

Funding Information:
Acknowledgments This study was supported by a grant from the Good Health R&D Project from the Ministry for Health, Welfare and Family, Republic of Korea (A050021), and in part by a grant from Brain Korea 21 Project for Medical Science.

All Science Journal Classification (ASJC) codes

Physiology
Gastroenterology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s10620-009-0983-1

Cite this

Park, Y. K., Lee, J. M., Kim, D. Y., Chang, H. Y., Kim, J. K., Lee, C. K., Park, J. Y., Ahn, S. H., Lee, K. S., & Han, K. H. (2010). Association between polymorphism of tumor necrosis factor-α promoter and response to lamivudine treatment in patients with chronic hepatitis B. Digestive diseases and sciences, 55(7), 2043-2048. https://doi.org/10.1007/s10620-009-0983-1

@article{133a6c87f0d746ed95bbd19a2acf7ca6,

title = "Association between polymorphism of tumor necrosis factor-α promoter and response to lamivudine treatment in patients with chronic hepatitis B",

abstract = "Background: TNF-α promoter polymorphism is known to play an important role in the immunopathogenesis of infection of hepatitis B virus. Aims: We investigated whether polymorphisms of TNF-α promoter at position -308 or -238 had associations with the response to lamivudine treatment. Methods: A total of 89 healthy subjects (control group) and 225 patients with chronic hepatitis B treated with lamivudine were included in this study. Polymorphisms of TNF-α promoter at position -308 and -238 were analyzed by polymerase chain reaction. Recruited patients were classified according to the outcome of lamivudine treatment into the responder (103 patients) or non-responder (122 patients) group. Results: The numbers of A allelic polymorphism of TNF-α promoter at position -238 were four (2.2%) in the control, five (2.4%) in the responder and 19 (7.8%) in the non-responder group. The A allele was noted significantly more frequently in the responder than non-responder group (P = 0.012). At position -308, a significant difference was observed between the control group (14; 7.9%) and total chronic hepatitis B patients (15; 3.3%) (P = 0.015). Conclusions: Our study demonstrated that the non-response to lamivudine treatment in patients with chronic hepatitis B might be related to the A allelic polymorphism of TNF-α promoter at position -238.",

author = "Park, {Yong Kwang} and Lee, {Jung Min} and Kim, {Do Young} and Chang, {Hye Young} and Kim, {Ja Kyung} and Lee, {Chun Kyon} and Park, {Jun Yong} and Ahn, {Sang Hoon} and Lee, {Kwan Sik} and Han, {Kwang Hyub}",

note = "Funding Information: Acknowledgments This study was supported by a grant from the Good Health R&D Project from the Ministry for Health, Welfare and Family, Republic of Korea (A050021), and in part by a grant from Brain Korea 21 Project for Medical Science.",

year = "2010",

month = jul,

doi = "10.1007/s10620-009-0983-1",

language = "English",

volume = "55",

pages = "2043--2048",

journal = "American Journal of Digestive Diseases",

issn = "0002-9211",

publisher = "Springer New York",

number = "7",

}

TY - JOUR

T1 - Association between polymorphism of tumor necrosis factor-α promoter and response to lamivudine treatment in patients with chronic hepatitis B

AU - Park, Yong Kwang

AU - Lee, Jung Min

AU - Kim, Do Young

AU - Chang, Hye Young

AU - Kim, Ja Kyung

AU - Lee, Chun Kyon

AU - Park, Jun Yong

AU - Ahn, Sang Hoon

AU - Lee, Kwan Sik

AU - Han, Kwang Hyub

N1 - Funding Information: Acknowledgments This study was supported by a grant from the Good Health R&D Project from the Ministry for Health, Welfare and Family, Republic of Korea (A050021), and in part by a grant from Brain Korea 21 Project for Medical Science.

PY - 2010/7

Y1 - 2010/7

N2 - Background: TNF-α promoter polymorphism is known to play an important role in the immunopathogenesis of infection of hepatitis B virus. Aims: We investigated whether polymorphisms of TNF-α promoter at position -308 or -238 had associations with the response to lamivudine treatment. Methods: A total of 89 healthy subjects (control group) and 225 patients with chronic hepatitis B treated with lamivudine were included in this study. Polymorphisms of TNF-α promoter at position -308 and -238 were analyzed by polymerase chain reaction. Recruited patients were classified according to the outcome of lamivudine treatment into the responder (103 patients) or non-responder (122 patients) group. Results: The numbers of A allelic polymorphism of TNF-α promoter at position -238 were four (2.2%) in the control, five (2.4%) in the responder and 19 (7.8%) in the non-responder group. The A allele was noted significantly more frequently in the responder than non-responder group (P = 0.012). At position -308, a significant difference was observed between the control group (14; 7.9%) and total chronic hepatitis B patients (15; 3.3%) (P = 0.015). Conclusions: Our study demonstrated that the non-response to lamivudine treatment in patients with chronic hepatitis B might be related to the A allelic polymorphism of TNF-α promoter at position -238.

AB - Background: TNF-α promoter polymorphism is known to play an important role in the immunopathogenesis of infection of hepatitis B virus. Aims: We investigated whether polymorphisms of TNF-α promoter at position -308 or -238 had associations with the response to lamivudine treatment. Methods: A total of 89 healthy subjects (control group) and 225 patients with chronic hepatitis B treated with lamivudine were included in this study. Polymorphisms of TNF-α promoter at position -308 and -238 were analyzed by polymerase chain reaction. Recruited patients were classified according to the outcome of lamivudine treatment into the responder (103 patients) or non-responder (122 patients) group. Results: The numbers of A allelic polymorphism of TNF-α promoter at position -238 were four (2.2%) in the control, five (2.4%) in the responder and 19 (7.8%) in the non-responder group. The A allele was noted significantly more frequently in the responder than non-responder group (P = 0.012). At position -308, a significant difference was observed between the control group (14; 7.9%) and total chronic hepatitis B patients (15; 3.3%) (P = 0.015). Conclusions: Our study demonstrated that the non-response to lamivudine treatment in patients with chronic hepatitis B might be related to the A allelic polymorphism of TNF-α promoter at position -238.

UR - http://www.scopus.com/inward/record.url?scp=77954423985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954423985&partnerID=8YFLogxK

U2 - 10.1007/s10620-009-0983-1

DO - 10.1007/s10620-009-0983-1

M3 - Article

C2 - 19830555

AN - SCOPUS:77954423985

VL - 55

SP - 2043

EP - 2048

JO - American Journal of Digestive Diseases

JF - American Journal of Digestive Diseases

SN - 0002-9211

IS - 7

ER -

Association between polymorphism of tumor necrosis factor-α promoter and response to lamivudine treatment in patients with chronic hepatitis B

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this